Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

To evaluate the effect of Lipopolysaccharide (LPS), a bacterial endotoxin on cochlear microcirculation, and its mode of action. Twenty-five Dunkin-Hartley guinea pigs were divided into five groups of five animals each. After surgical preparation, cochlear microcirculation was quantified by in vivo fluorescence microscopy. Placebo or LPS (1 mg, 10 µg, and 100 ng) was applied topically, and microcirculation was measured before and twice after application. A fifth group was pretreated with etanercept, a tumor necrosis factor (TNF) antagonist, and afterward the lowest LPS concentrations that yielded significant results (10 µg) were applied. In the groups that had been treated with 1 mg and 10 µg LPS, a significant drop in cochlear microcirculation was observed after 30 (.791 ± .089 Arbitrary Units (AU), compared to baseline, and .888 ± .071AU) and 60 (.756 ± .101 AU and .817 ± .124 AU, respectively) minutes. The groups that had been treated with 100 ng LPS and that had been pretreated with etanercept showed no significant change in cochlear blood flow compared to placebo. Lipopolysaccharide shows a dose-dependent effect on cochlear microcirculation; this effect can already be observed after 30 min. Pretreatment with etanercept can abrogate this effect, indicating that TNF mediates the effect of LPS on cochlear microcirculation. © 2021 The Authors. Microcirculation published by John Wiley & Sons Ltd.

Citation

Friedrich Ihler, Saskia Freytag, Benedikt Kloos, Jennifer Lee Spiegel, Frank Haubner, Martin Canis, Bernhard G Weiss, Mattis Bertlich. Lipopolysaccharide decreases cochlear blood flow dose dependently in a guinea pig animal model via TNF signaling. Microcirculation (New York, N.Y. : 1994). 2021 May;28(4):e12681

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33501679

View Full Text